BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230 million series B round co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures and SoftBank Vision Fund 2i, with participation from Qatar Investment...
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

Several inflammatory and cancer indications will soon see human proof-of-concept data from small molecules targeting the kinase IRAK4, as a class of at least eight such molecules makes its way through early-stage trials. IRAK4 mediates innate...
BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

...detectors TLR7 and TLR8; Silverback’s therapies agonize TLR8.Wan...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...half of the $241.5 million it wound up with.Lead product candidate SBT6050, which links a TLR8...
...just over 10%. TARGETSHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 TLR8 - Toll-like receptor 8 Paul...
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...existing investors. The company’s lead candidate SBT6050, a conjugate comprising a HER2-targeting mAb linked to a TLR8...
...participated. TARGETSHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2IL-17A - Interleukin-17AIL-17F - Interleukin-17FTLR8 - Toll-like receptor 8 Paul...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax $5 million up front...
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

Atlas-backed Kymera has at least one comparator among preclinical protein degradation companies as it seeks a NASDAQ listing -- and it could soon be followed by another company in the same category. A regulatory filing...
Items per page:
1 - 10 of 1278